VKTX - Bull Thesis
BULL THESIS
VKTX overall corporate summary
Focus on novel therapeutics for metabolic and endocrine diseases, especially NASH
As of 12/31/21 VKTX had $202.1 million (1yr) cash/equiv.
VK2809 (TRb Agonist) (NAFLD)
~100 million people in US. have NAFLD (learn more)
Positive proof of concept phase 2 data readout in 2018
Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in LDL-C in Patients Receiving VK2809 source
83.3% of patients had >30% reduction in liver fat content.
Stronger results than competitor MDGL, with same MOA (TRb Agonist).
Following this readout, stock price soared over 100%
One of the strongest readouts ever in NAFLD, according to the company.
VK2809 (TRb Agonist) NASH
~20 percent of people with NAFLD have NASH
Potentially 1st approved NASH therapeutic
NASH market is very large (est. >$50B by 2029)
Currently in Ph 2b VOYAGE with initial data expected YE 2022
Possible Run-Up and Mover to Watch event
Stronger clinical data than competitor MDGL.
VK0214 (TRb Agonist) X-ALD
Rare disease (~1 in 17,000 newborns) without current effective therapy
Positive preclinical proof of concept data
Potential to be best in-class oral, small molecule TRβ therapeutic for X-ALD
Phase 1 safety and PK trial was well tolerated at all doses (source)
Efficacy data readout expected in 2022
VK2735 (subQ dual agonist of GLP-1 and GIP receptors) metabolic disorders
Phase 1 trial in healthy volunteers under way
Data expected 2H '22
First clinical compound from VKTX R&D
Expands VKTX pipeline outside of TRb agonists
JM 2/10/22 (EJV 2/13/22 added VK2735))
See the bull/bear analysis in our BPIQ Pro Forum post here and the full bull/bear analysis w/ Amp view in our Amp Premium Forum post here. To become a subscriber Learn more here.